))
Fibrobiologics walks the unconventional financing path
Manage episode 418434372 series 2949057
Content provided by BioWorld Insider Podcast. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by BioWorld Insider Podcast or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
A non-traditional route for financing has been the path to success for Fibrobiologics Inc. In the newest BioWorld Insider podcast, CEO Pete O’Heeron offers insight into the company’s unusual path to a Nasdaq listing in January. SPACs, reverse mergers and traditional IPOs weren’t attractive enough for Fibrobiologics’ management or board, so they decided to go public through a direct listing with no banks as underwriters. It took about seven months to get the company ready for its listing, an around-the-clock effort that O’Heeron said was worth the effort. “We couldn’t be more happy with the outcome,” he said. Download transcript
…
continue reading
38 episodes
Share
